The article reports on the documents released by the Chinese government indicating its actions against pharmaceutical companies that have allegedly produced or re-sold mislabeled, adulterated and improperly produced ginkgo extracts in November 2015. Topics covered include the China Food and Drug Administration (CFDA), Wanbangde (Hunan) Natural Pharmaceutical Co., and the production of false raw material purchasing records.